Trial Profile
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite Stable Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Azacitidine; Pembrolizumab
- Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oropharyngeal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ECHO 206
- Sponsors Incyte Corporation
- 26 May 2023 Status changed from recruiting to completed.
- 22 Apr 2023 Results(n=70) assessing safety of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors published in the British Journal of Cancer
- 15 Jul 2020 This trial has been completed in United Kingdom (Date: 2 Mar 2020).